Comprehensive Intellectual Property Protection
Pneuma’s patent portfolio protects core aerosol generation methods that are difficult to replicate through conventional nebulization or mesh-based approaches.
57 issued patents
135 pending applications
Pneuma Respiratory has built a formidable intellectual property portfolio that provides extensive protection for our innovative technology, including coverage for the following critical aspects:
Ultra-fine aerosol generation (<1 μm droplets)
Low-shear delivery for fragile biologics
Breath-actuation detection & timing control
Dose tracking & High Dose Confidence (HDC) logic
Inhalation-pattern sensing & voice coaching
Multi-formulation compatibility (aqueous, nano/micro suspensions, biologics)
Cloud-based adherence reporting and analytics.
Key foundational patents include:
“Droplet Delivery Device for Delivery of Fluids to the Pulmonary System and Methods of Use” (filed in 2016).
“Droplet Delivery Device with Membrane-Driven Aerosolization” (filed in 2021).
Pharmaceutical delivery platform hallmarks:
Ultra-Fine Droplet Precision – Precision control over aerosol droplet size, allowing targeted delivery to different regions of the lung.
High Respirable Fraction – Exceeds 90% aerosol delivery to the lungs. This maximizes the amount of drug deposited in the lungs, thereby reducing the systemic dose required to achieve a given therapeutic effect, which can improve the safety profile of many respiratory treatments.
Versatile Drug Compatibility – Adaptable to a wide range of pharmaceutical compounds, including large-molecule biologics that are challenging to deliver through traditional methods.
Breath-Actuated Delivery – Seamlessly delivers medications as patients breathe, improving ease of use, adherence, and comfort.
Fully Digital Design – Enables precise dosing, customization, and remote monitoring through a connected, app-compatible system, enhancing treatment management and patient engagement.
Broad Application Potential – Designed for various therapeutic areas, including lung conditions (asthma, COPD), cancer (non-small cell lung cancer), and systemic diseases requiring inhaled delivery of complex molecules.